Meghan Scanlon - Feb 22, 2022 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Role: SVP,Pres,Urology Pelvic Health
Signature: /s/ Susan Thompson, Attorney-in-Fact
Stock symbol: BSX
Transactions as of: Feb 22, 2022
Transactions value $: $0
Form type: 4
Date filed: 2/24/2022, 03:22 PM
Previous filing: Feb 23, 2022
Next filing: Mar 2, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BSX	Performance Share Units	Award	$0	+8.28K		$0.00	8.28K	Feb 22, 2022	Common Stock	8.28K		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F2	On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023.

Content

Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.

On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023.